United States

ForwardVue

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

ForwardVue Pharma Secures Funding to Advance Pre-Clinical Development Programs

Lead Product(s): Caroboxyamidotriazole

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding August 26, 2020

Details:

ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Emerald Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO

Lead Product(s): Tetrahydrocannabinol

Therapeutic Area: Ophthalmology Product Name: NB-1111

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2020

Details:

Emerald Bioscience is working to complete the final preclinical steps for NB-1111, its promising glaucoma product candidate, and preparing for first human study in Australia.

Retrotope

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Retrotope Starts IND Enabling Studies for its Second D-PUFA Drug Candidate, Targeting the Treatment of AMD and Related Retinal Pathologies

Lead Product(s): Docosahexaenoic Acids

Therapeutic Area: Ophthalmology Product Name: RT011

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.

Biogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Biogen Joins Harvard in Gene Therapy Pact to Fight Eye Disease

Lead Product(s): AAV gene therapy

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Massachusetts Eye and Ear

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 06, 2020

Details:

The gene at the center of the new agreement, PRPF31, has been linked to autosomal dominant retinitis pigmentosa. PRPF31 mutations are believed to cause an estimated 25% of all retinitis pigmentosa cases.

AsclepiX Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

AsclepiX Therapeutics Announces $35 Million Series A Financing

Lead Product(s): AXT107

Therapeutic Area: Ophthalmology Product Name: AXT107

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund

Deal Size: Undisclosed Upfront Cash: $35.0 million

Deal Type: Series A Financing June 24, 2020

Details:

Proceeds will be used to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials.

Rezolute

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

Lead Product(s): RZ402

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

RZ402 demonstrated an excellent ADME (absorption, distribution, metabolism and excretion) profile, and moderate renal clearance with plasma levels remained above EC50 for 24 hours after dosing, consistent with a daily oral dose regimen.

SanBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Sanbio and Ocumension Ink Pact For Research, Development of Innovative Stem Cell Therapies for Ophthalmic Diseases

Lead Product(s): SB623

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Ocumension

Deal Size: $71.0 million Upfront Cash: $6.0 million

Deal Type: Agreement April 01, 2020

Details:

Ocumension obtains exclusive rights from SanBio to develop and commercialize SB623 and MSC2 in Greater China for ophthalmic indications.

Ocugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

Lead Product(s): NR2E3-AAV

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy.

Graybug Vision

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Graybug Vision Presents Preclinical Results for GB-401

Lead Product(s): GB-401

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

The study showed that GB-401 achieved sustained ocular drug levels and reduced IOP in experimental animal models after a single intravitreal or subconjunctival injection.